Clinical Trial Update: Safety Study of 2.0mg Lucentis to Treat Polypoidal Choroidal Vasculopathy [Phase 1, Phase 2]

View source ↗

Summary

A safety-focused clinical trial update for 2.0 mg Lucentis in polypoidal choroidal vasculopathy (Phase 1/2) with completed status and results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Polypoidal Choroidal Vasculopathy

Drugs mentioned

• Lucentis (ranibizumab)

Snippet

Sponsor: Southeast Retina Center, Georgia | Conditions: Polypoidal Choroidal Vasculopathy | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-12-12